| 前收盘价格 | 1.57 |
| 收盘价格 | 1.53 |
| 成交量 | 53,929 |
| 平均成交量 (3个月) | 124,676 |
| 市值 | 40,235,016 |
| 价格/销量 (P/S) | 0.160 |
| 股市价格/股市净资产 (P/B) | 2.05 |
| 52周波幅 | |
| 利润日期 | 28 Jul 2025 - 1 Aug 2025 |
| 营业毛利率 | -72.72% |
| 营业利益率 (TTM) | -124.00% |
| 稀释每股收益 (EPS TTM) | -100.39 |
| 季度收入增长率 (YOY) | 145.50% |
| 季度盈利增长率 (YOY) | -60.90% |
| 总债务/股东权益 (D/E MRQ) | 399.66% |
| 流动比率 (MRQ) | 0.190 |
| 营业现金流 (OCF TTM) | -12.34 M |
| 杠杆自由现金流 (LFCF TTM) | -22.50 M |
| 资产报酬率 (ROA TTM) | -17.45% |
| 股东权益报酬率 (ROE TTM) | -147.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Celularity Inc. | 混合的 | 混合的 |
AIStockmoo 评分
0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.83 |
|
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 55.61% |
| 机构持股比例 | 14.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| C V Starr & Co Inc | 31 Dec 2024 | 764,069 |
| Hb Wealth Management, Llc | 31 Mar 2025 | 40,763 |
| Biltmore Family Office, Llc | 31 Dec 2024 | 35,000 |
| Keynote Financial Services Llc | 31 Dec 2024 | 25,023 |
| Ipg Investment Advisors Llc | 31 Dec 2024 | 17,169 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合